Galderma Group AG GALD

ZUG, Switzerland, September 30, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and ef

ZUG, Switzerland, September 23, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin lo

Galderma Group (SWX:GALD) has just raised its full-year 2026 net sales growth guidance to a range of 19% to 21% at constant currency, after reporting 24.6% year-on-year net sales growth in the first half. Galderma Group’s recent guidance lift comes after a mixed year for the stock, with the share price up 1.96% on the day and 3.63% over the past week, but down 6.00% over 30 days and 8.01% over 90 days. The 1 year total shareholder return of 14.13% points to stronger longer term momentum...

ZUG, Switzerland, September 21, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies.

ZUG, Switzerland, September 16, 2026--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its Restylane hyaluronic ac

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

ZUG, Switzerland, August 11, 2026--Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3

Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to “overweight” from “equal-weight” and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth forecasts for the company’s Nemluvio drug and injectable aesthetics business after the Swiss dermatology company posted strong first-half 2026 results.

Galderma Group AG (GDERF) reports robust sales growth and strategic advancements, while navigating regulatory and market challenges.

ZUG, Switzerland, July 23, 2026--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026.

ZUG, Switzerland, July 20, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively.

ZUG, Switzerland, July 07, 2026--Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns.

Investing.com -- Swiss dermatology companyGalderma Group AG (SIX:GALD) fell nearly 6% on Wednesday after the U.S. Food and Drug Administration declined to approve its wrinkle treatment RelabotulinumtoxinA, delaying the product's planned entry into the U.S. aesthetics market. The stock dropped 5.8% to CHF 173.25, sharply underperforming the benchmark SMI which traded little changed in afternoon dealings. The FDA issued a Complete Response Letter, citing manufacturing-related observations identifi

ZUG, Switzerland, July 01, 2026--Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application ("BLA") for RelabotulinumtoxinA with the U.S. Food and Drug Administration ("FDA"). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI)

ZUG, Switzerland, June 11, 2026--Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product perf

Galderma Group AG - Unsponsored ADR (GALDY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

As European markets face headwinds with the pan-European STOXX Europe 600 Index down 2.54% and major indices like Germany’s DAX and France’s CAC 40 seeing declines, investors are increasingly focused on finding opportunities amidst the broader economic uncertainties. In such an environment, identifying stocks that are estimated to be trading below their fair value can offer potential for long-term growth, especially when traditional defensive sectors show resilience in times of geopolitical...